Growth differentiation factor-15 is a predictive biomarker in primary ventricular fibrillation: The RUTI-STEMI-PVF study

Background: Primary ventricular fibrillation is an ominous complication of ST-segment elevation myocardial infarction, and proper biomarkers for risk prediction are lacking. Growth differentiation factor-15 is a marker of inflammation, oxidative stress and hypoxia with well-established prognostic va...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal. Acute cardiovascular care 2020-11, Vol.9 (4_suppl), p.S161-S168
Main Authors: Garcia-Garcia, C, Rueda, F, Lupon, J, Oliveras, T, Labata, C, Ferrer, M, Cediel, G, De Diego, O, Rodriguez-Leor, O, Carrillo, X, Bayes-Genis, A
Format: Article
Language:English
Subjects:
Biomarkers - blood
Coronary Angiography
Electrocardiography
Female
Follow-Up Studies
Growth Differentiation Factor 15 - blood
Humans
Male
Middle Aged
Predictive Value of Tests
Prognosis
Prospective Studies
ST Elevation Myocardial Infarction - complications
ST Elevation Myocardial Infarction - diagnosis
ST Elevation Myocardial Infarction - physiopathology
Stroke Volume
Ventricular Fibrillation - blood
Ventricular Fibrillation - etiology
Ventricular Function, Left
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Primary ventricular fibrillation is an ominous complication of ST-segment elevation myocardial infarction, and proper biomarkers for risk prediction are lacking. Growth differentiation factor-15 is a marker of inflammation, oxidative stress and hypoxia with well-established prognostic value in ST-segment elevation myocardial infarction patients. We explored the predictive value of growth differentiation factor-15 in a subgroup of ST-segment elevation myocardial infarction patients with primary ventricular fibrillation. Methods: Prospective registry of ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention from February 2011–August 2015. Growth differentiation factor-15 concentrations were measured on admission. Logistic regression and Cox proportional regression analyses were used. Results: A total of 1165 ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention (men 78.5%, age 62.3±13.1 years) and 72 patients with primary ventricular fibrillation (6.2%) were included. Compared to patients without primary ventricular fibrillation, median growth differentiation factor-15 concentration was two-fold higher in ST-segment elevation myocardial infarction patients with primary ventricular fibrillation (2655 vs 1367 pg/ml, p
ISSN:2048-8726
2048-8734
DOI:10.1177/2048872618797599